Sfoglia per AUTORE
TUCCI M
Collezione AO Cuneo

  

Items : 4

Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. in Journal of translational medicine / J Transl Med. 2022 Apr 5;20(1):159. doi: 10.1186/s12967-022-03359-x.

2022
AO Cuneo

Guida M; Bartolomeo N; Quaresmini D; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Valente M; Sciacovelli AM; Chiarion Sileni V; Ascierto PA; Stigliano L; Strippoli S;

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.

2021
ASL Asti
AO Cuneo
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
ASL Biella

Berruti A; Tucci M; Gennari A; Baier S; Bellissimo AR; Ciccone G; Montagnani F; Comandone A; Chiappino I; Dal Canton O; Masini C; Sacco C; Zamparini M; Sirotova Z; Fea E; Valcamonico F; Vanella P; Ortega C; Buttigliero C; Prati V; Bianchi S; Mosca A; Dalla Volta A; Amoroso D;

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. in Cancers / Cancers (Basel). 2021 Jan 26;13(3):475. doi: 10.3390/cancers13030475.

2021
AO Cuneo

Ascierto PA; Chiaron Sileni V; Gambale E; Quaresmini D; De Risi I; Queirolo P; Ridolfi L; Occelli M; Spagnolo F; Tucci M; Minisini AM; Di Giacomo AM; Pigozzo J; Quaglino P; Madonna G; Bartolomeo N; Guida M; Stigliano L; Strippoli S; On Behalf Of The Italian Melanoma Intergroup Imi Study;

The density and spatial tissue distribution of CD8(+) and CD163(+) immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. in Journal for immunotherapy of cancer / J Immunother Cancer. 2019 Nov 15;7(1):308. doi: 10.1186/s40425-019-0797-4.

2019
AO Cuneo

Cattaneo L; Carnevale-Schianca F; Baroni G; Queirolo P; Quaglino P; Consoli F; Vallacchi V; Portelli F; Occelli M; Tucci M; Di Giacomo AM; Sileni VC; De Penni R; Guida M; Di Guardo L; Del Vecchio M; Nassini R; De Logu F; Merelli B; Rodolfo M; Valeri B; Cossa M; Rulli E; Massi D; Minisini A; Palmieri G; Rivoltini L; Mandalà M;